Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS- On the radar: Another early batch of Q2 earnings

Thu, 16th Jul 2020 07:45

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

ON THE RADAR: ANOTHER EARLY BATCH OF Q2 EARNINGS (0636 GMT)

European shares are seen opening in the red as risk appetite took a hit by concerns about
deteriorating U.S.-China relations. Investors also have to digest a slew of earnings reports,
which show the size of lockdowns damage.

France's Alstom reports a 27% slump in Q1 sales while Richemont Q1 sales nearly halve after
COVID-19 disruption. Richemont shares are down 4% in pre-market trading.

On a brighter note, Norway's Telenor Q2 earnings beat estimates and the company said it
expects a single-digit decline in its subscription and traffic revenues this year. Experian
first-quarter revenue falls less than feared.

Germany's Zalando shares are up almost 5% in pre market after the online fashion retailer
raised full year guidance as more people shop online.

Global miner Anglo sticks to most of its 2020 output targets but Q2 hit by COVID-19.

Swedish medical equipment maker Getinge also reported a jump in core profit and
order intake in the second quarter as demand for ventilators and other life support equipment
surged.

More news about COVID-19 treatment and vaccine: Early-stage human trial data on a vaccine
being developed by AstraZeneca and Oxford University will be published on July 20, The
Lancet medical journal said. Novartis's Sandoz division says will not make a profit on
15 generic drugs it is making available to developing countries to treat symptoms of COVID-19,
the Swiss drugmaker said on Thursday.

(Joice Alves)

*****

MORNING CALL: U.S.-CHINA TENSIONS HIT ONE MORE TIME (0540 GMT)

European shares are seen opening in the red as risk appetite weakened by growing concerns
about deteriorating U.S.-China relations.

Worries about a dispute between the world's two largest economies over the control of
advanced technologies and the protection of civil liberties in Hong Kong pushed Asian stocks and
U.S. futures down.

Even news that China's economy rebounded more than hoped in the second quarter from a record
slump was not enough to cheer investors up. A surge in coronavirus cases, which is prompting
some governments to reimpose containment measures, is also not helping sentiment.

After touching a one-month highs yesterday on vaccine hopes, European markets are set to
follow Asia lower. Investors will also have to digest a slew of earnings, which will show the
size of lockdowns damage.

Financial spreadbetters at IG expect London's FTSE to open 20 points lower at 6,273,
Frankfurt's DAX to open 97 points lower at 12,834 and Paris' CAC to open 26 points lower at
5,083.

(Joice Alves)

*****

More News
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.